US OptionsDetailed Quotes
CLRB240719P2500
- 0.09
- -0.16-64.00%
15min DelayClose Jul 19 15:58 ET
0.09High0.09Low
0.09Open0.25Pre Close20 Volume240 Open Interest2.50Strike Price180.00Turnover971.99%IV4.37%PremiumJul 19, 2024Expiry Date0.00Intrinsic Value100Multiplier0DDays to Expiry0.09Extrinsic Value100Contract SizeAmericanOptions Type-0.4484Delta1.5760Gamma28.00Leverage Ratio-1.3292Theta0.0000Rho-12.55Eff Leverage0.0001Vega
Cellectar BioSciences Stock Discussion
Cellectar Biosciences and City of Hope Cancer Center Enter Collaboration to Evaluate Iopofosine I 131 in Mycosis Fungoides
Cellectar Biosciences (NASDAQ: CLRB) has formed a strategic partnership with City of Hope Cancer Center to evaluate the efficacy of its lead drug, iopofosine I 131, in treating mycosis fungoides (MF), a rare form of non-Hodgkin's lymphoma (NHL). This collaboration aims to initiate trials with around 10 patients by late 2024 or early 202...
$Iovance Biotherapeutics(IOVA.US)$ Phase 2
$Supernus Pharmaceuticals(SUPN.US)$ Phase 2a
$BRANDES INTERNATIONAL ETF(BINV.US)$ Phase 2a
$MorphoSys(MOR.US)$ Phase 2
$Nuvation Bio(NUVB.US)$ Phase 2
$ALX Oncology(ALXO.US)$ Phase 2
$BioXcel Therapeutics(BTAI.US)$ Phase 2
$Purple Biotech(PPBT.US)$ Phase 2
$Arcus Biosciences(RCUS.US)$ Phase 2
$Medicenna Therapeutics(MDNAF.US)$ Phase 2b
$Affimed NV(AFMD.US)$ Phase 2
$Barinthus Biotherapeutics(BRNS.US)$ Phase 2b...
4 MINUTES AGO, 6:40 AM EST
VIA GLOBENEWSWIRE
2 MINUTES AGO, 6:40 AM EST
VIA GLOBENEWSWIRE
$Dyne Therapeutics(DYN.US)$ 4% Closing of public offering
$Geron(GERN.US)$ 4% Participate @ B. Riley Sec. Conf. '24
$ZEALAND PHARMA AS SPON ADR EACH REP 1 ORD SHS(ZEAL.US)$ 2% Capital increase
$XOMA Corp(XOMA.US)$ 1% Arimoclomol NDA filing accepted
$Cellectar BioSciences(CLRB.US)$ 1% Topline results @ conf. call
$CytomX(CTMX.US)$ 0% Present @ B. Riley Sec. Conf. '24
No comment yet